The First FDA-Approved Treatment for Chronic Hand Eczema: Anzupgo (Delgocitinib) Cream, a pan-JAK inhibitor

Chronic hand eczema (CHE) - a persistent, often debilitating inflammatory skin condition affecting the hands - has long frustrated patients, allergists and dermatologists alike.

Many endure recurring flares, pain, itching, cracking, and impaired daily function, with limited options beyond topical corticosteroids, which may lose effectiveness over time or cause side effects with prolonged use.

LEO Pharma's Anzupgo (delgocitinib) cream - a steroid-free, topical pan-JAK inhibitor - is available by prescription in the United States for adults with moderate to severe CHE. This marks the first and only FDA-approved therapy specifically indicated for this condition in adults who have not responded adequately to topical corticosteroids or for whom steroids are not advisable.

Anzupgo (delgocitinib 20 mg/g cream) targets the JAK-STAT pathway to reduce inflammation by inhibiting multiple JAK enzymes (pan-JAK inhibition).

Applied twice daily to affected areas on the hands and wrists, it offers a non-systemic, targeted topical approach with usage limits to minimize risks (no more than 30 grams per 2 weeks or 60 grams per month).

No major safety signals emerged in trials beyond known JAK class considerations (e.g., infection risk monitoring, periodic skin exams for non-melanoma skin cancer).

Contact Dermatitis - An Approach to Treatment (click to enlarge the image).

References:

https://www.dermatologytimes.com/view/delgocitinib-now-available-in-the-us-for-che